Unknown

Dataset Information

0

Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment.


ABSTRACT: In patients with renal impairment (n?=?22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r 2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

SUBMITTER: Souza E 

PROVIDER: S-EPMC7179609 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment.

Souza Ernane E   Crass Ryan L RL   Felton Jeremy J   Hanaya Kengo K   Pai Manjunath P MP  

Antimicrobial agents and chemotherapy 20200421 5


In patients with renal impairment (<i>n</i> = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (<i>r</i><sup>2</sup> = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myel  ...[more]

Similar Datasets

| S-EPMC7934392 | biostudies-literature
| S-EPMC6658752 | biostudies-literature
| S-EPMC9303631 | biostudies-literature
| S-EPMC9198091 | biostudies-literature
| S-EPMC3899495 | biostudies-literature
| S-EPMC8670561 | biostudies-literature
| S-EPMC8932715 | biostudies-literature
| S-EPMC3848055 | biostudies-literature
2022-03-17 | GSE198741 | GEO
| S-EPMC4291359 | biostudies-literature